Affiliation:
1. Helsana Insurance Group
2. Zurich University of Applied Sciences
Abstract
Abstract
Purpose: Antidepressant use has increased in many European countries, mostly driven by longer treatment duration. The aim of this study was to provide prevalence rates of long-term users of antidepressants for the Swiss population over the last decade and to investigate associated factors for longer use.
Methods: We examined the prevalence rates of individuals with at least one prescription for antidepressants using longitudinal health claims data. To compare different lengths of prescription duration, we defined short-term (<6 months), medium-term (6-12 months) and long-term users (>12 months). We applied a binary logistic regression model to investigate the effects of population characteristics and treatment patterns on long-term compared to short- and medium-term users.
Results: In 2021, 9% of the Swiss population (n=770 698) received at least one antidepressant prescription. This one-year-prevalence remained stable since 2013. In 2020, the proportion of long-term users was 69.4%, with steady increase from 2014 to 2020. The numbers of medium- and short-term users have decreased during this period. Older age, being a woman, living in an urban area, living in the Italian speaking part of Switzerland, living in a nursing home, being enrolled in a standard care plan, and receiving psychiatric or psychotherapeutic care were factors associated with long-term users.
Conclusion: The proportion of long-term users in Switzerland is steadily increasing. Taking antidepressants longer than recommended may indicate possible overprescribing. Given the ongoing debate about the confounding effects of relapse and withdrawal, more research is needed to investigate antidepressants overprescribing, particularly for older people.
Publisher
Research Square Platform LLC
Reference40 articles.
1. Quantifying the global burden of mental disorders and their economic value;Arias D;EClinicalMedicine,2022
2. Global, regional, and national burden of 12 mental disorders in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019;GBD 2019 Mental Disorders Collaborators;The Lancet Psychiatry,2022
3. American Psychological Association (2019) Clinical Practice Guideline for the Treatment of Depression Across Three Age Cohorts. https://www.apa.org/depression-guideline. Accessed 17 Mar 2023
4. National Institute for Health and Care Excellence (2020) Generalised anxiety disorder and panic disorder in adults: management. https://www.nice.org.uk/guidance/cg113. Accessed 17 Mar 2023
5. Lunghi C, Dugas M, Lecrlerc J, Poluzzi E, Marineau C, Carnovale V, Stéran T, LeBlanc A (2022) Global prevalence of antidepressant drug utilization in the community: protocol for a systematic review. BMJ Open e062197(12). Doi:10.1136/bmjopen-2022-062197